Siremadlin is an oral biologic agent that is a selective inhibitor of the p53-MDM2 interaction and is being investigated for the treatment of patients with myeloid malignancies after showing single agent activity in preclinical studies. the safety profile of Siremadlin did not differ significantly between tumor types and treatment regimens.